Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL1333 DDI study in healthy subjects
NCT04643249Phase 1Completed
- Sponsor
- Abliva AB
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of napazimone in primary mitochondrial disease (PMD), sponsored by Abliva AB. Primary endpoint: Pharmacokinetics of Probe Drugs at Day 14. Started Nov 2020; status: completed.
02
Drugs
napazimone
03
Conditions
primary mitochondrial disease (PMD)
Beyond the preview
Go deeper on NCT04643249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643249.